Can Monster Beverage (MNST) Stock Continue to Grow Earnings?
Have you been eager to see how Northern Trust Corporation NTRS performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this IL-based popular bank’s earnings release this morning:
An Earnings Miss
Northern Trust came out with earnings per share of $1.58, missing the Zacks Consensus Estimate of $1.60. Higher expenses were primarily responsible for the earnings miss.
How Was the Estimate Revision Trend?
You should note that the earnings estimate revisions for Northern Trust depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained stable over the last seven days.
Moreover, Northern Trust has a decent earnings surprise history. Before posting earnings miss in Q3, the company delivered positive surprises in all the prior four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 7.47% in the trailing four quarters.
Northern Trust Corporation Price and EPS Surprise
Northern Trust Corporation Price and EPS Surprise | Northern Trust Corporation Quote
Revenue Came In Lower Than Expected
Northern Trust posted revenues of $1.48 billion, lagging the Zacks Consensus Estimate of $1.51 billion. However, it compared favorably with the year-ago number of $1.35 billion.
Key Stats to Note:
- Total assets under custody jumped 6% year over year.
- Total assets under management increased 4%.
- Return on average common equity was 15.1%.
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Northern Trust. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look unfavorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Check back later for our full write up on this Northern Trust earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Northern Trust Corporation (NTRS) : Free Stock Analysis Report
To read this article on Zacks.com click here.